Numis Securities Ltd reiterated their buy rating on shares of Horizon Discovery Group PLC (LON:HZD) in a research note published on Tuesday morning. Numis Securities Ltd currently has a GBX 260 ($3.39) target price on the stock.
Several other analysts have also recently weighed in on the company. Panmure Gordon dropped their price objective on Horizon Discovery Group PLC from GBX 270 ($3.52) to GBX 205 ($2.68) and set a buy rating for the company in a report on Tuesday, September 20th. Beaufort Securities reissued a speculative buy rating on shares of Horizon Discovery Group PLC in a report on Wednesday, September 14th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Horizon Discovery Group PLC has a consensus rating of Buy and an average target price of GBX 217.25 ($2.84).
Horizon Discovery Group PLC (LON:HZD) opened at 154.00 on Tuesday. Horizon Discovery Group PLC has a 12 month low of GBX 125.00 and a 12 month high of GBX 188.06. The company’s market cap is GBX 144.95 million. The company’s 50-day moving average is GBX 160.33 and its 200 day moving average is GBX 160.73.
About Horizon Discovery Group PLC
Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.
Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.